Atorvastatin calcium tablets-induced rhabdomyolysis in a patient without OATP-SLCO1B1 C521T mutation
10.3760/cma.j.issn.1008-5734.2018.05.011
- VernacularTitle:阿托伐他汀钙片致OATP-SLCO1B1 C521T基因非突变患者横纹肌溶解
- Author:
Guangyan MU
1
;
Qian XIANG
1
;
Kun HU
1
;
Yimin CUI
1
Author Information
1. 100032,北京大学第一医院药剂科
- Publication Type:Journal Article
- Keywords:
Hydroxymethylglutaryl-CoA reductase inhibitors;
rhabdomyolysis;
genetics
- From:
Adverse Drug Reactions Journal
2018;20(5):376-377
- CountryChina
- Language:Chinese
-
Abstract:
A 55-year-old female patient with hyperlipemia received atorvastatin calcium tablets 20 mg,once daily orally.Two years later,the patient's legs appeared ecchymosis with distending pain and numbness.Laboratory tests showed serum myoglobin 682 μg/L and creatine kinase 1 007 U/L.She had not received any other drugs during the same period.Atorvastatin-induced rhabdomyolysis was considered.Atorvastatin was stopped,and the patient received symptomatic and supportive treatment.Twenty days later,her symptoms disappeared and her serum myoglobin and creatine kinase level turned to normal.A gene test of SLCO1B1 C521T polymorphism of organic anion transporting polypeptides associated with statin-induced muscle injury was detected after rhabdomyolysis,and the result showed TT genotype (non-mutant genotype).This suggested that the SLCO1B1 C521T genotypes could not predict the myotoxicity of statins accurately.
